EUR 1.110.032.63%

Chairman of the Board, Chief Scientific Officer

Dr. Karl Johe Ph.D. is Chairman of the Board and Chief Scientific Officer of Neuralstem Inc. since 1996. Dr. Johe has over 15 years of research and laboratory experience. Dr. Johe is the sole inventor of Neuralstems granted stem cell patents and is responsible for the strategic planning and development of our therapeutic products. Dr. Johe received his Bachelor of Arts Degree in Chemistry and a Masters Degree from the University of Kansas. Dr. Johe received his doctorate from the Albert Einstein College of Medicine of Yeshiva University. From 1993 to January 1997 Dr. Johe served as a Staff Scientist at the Laboratory of Molecular Biology of the National Institute of Neurological Disease and Stroke in Bethesda Maryland. While holding this position Dr. Johe conducted research on the isolation of neural stem cells the elucidation of mechanisms directing cell type specification of central nervous system stem cells and the establishment of an in vitro model of mammalian neurogenesis. In evaluating Dr. Johes specific experience qualifications attributes and skills in connection with his appointment to our board we took into account his extensive experience in international science and business communities. Dr. Johe is also multilingual.

Age: 53 Chairman Since 1996

49 60 2740 9000 http://www.curasan.de

Johe received his doctorate from the Albert Einstein College of Medicine of Yeshiva University. From 1993 to January 1997, Dr. Johe served as a Staff Scientist at the Laboratory of Molecular Biology of the National Institute of Neurological Disease and Stroke in Bethesda, Maryland. While holding this position, Dr. Johe conducted research on the isolation of neural stem cells, the elucidation of mechanisms directing cell type specification of central nervous system stem cells and the establishment of an in vitro model of mammalian neurogenesis.

Management Efficiency

The company has return on total asset (ROA) of (15.0) % which means that it has lost $15.0 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (35.94) % meaning that it generated substantial loss on money invested by shareholders.

The company has accumulated 427 K in total debt with debt to equity ratio (D/E) of 6.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Curasan AG has Current Ratio of 1.29 suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due.